title: Cisplatin-based combination chemotherapy in carcinoma of the fallopian tube.
abstract: Forty-three cases of primary tubal adenocarcinoma were treated at Memorial Sloan-Kettering Cancer Center between 1979 and 1989. Thirty-eight patients who received cisplatin-based combination chemotherapy following primary surgery were reviewed. The mean patient age was 59 years, with 86% postmenopausal. Distribution by stage was as follows: I, 3 (7%); II, 4 (11%); III, 27 (71%); and IV, 4 (11%). Median follow-up from the time of diagnosis was 62 months (range, 5-132). Overall survival for all 38 patients by Kaplan-Meier analysis was 51% at 5 years. Excluding stage I, patients with no residual disease following surgery had a significantly higher 5-year survival (83%) than those left with gross residual disease (28%). Twenty-six patients underwent a second-look procedure. Of the 21 patients with advanced (stages III, IV) disease undergoing reexploration, 11 (52%) had a negative second-look and 10 (48%) were positive. Ten of the eleven patients with a negative second-look remain clinically free of disease with a median follow-up of 49 months. One patient with stage III disease had recurred after 47 months. Carcinoma of the fallopian tube appears to respond favorably to cisplatin-based multiagent chemotherapy. Patients with advanced-stage disease who achieve a negative second-look appear to have an improved possibility of remaining disease-free over similar-stage patients with ovarian cancer.
authors.affiliation: Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
authors.forename: R R
authors.initials: RR
authors.lastname: Barakat
authors.forename: S C
authors.initials: SC
authors.lastname: Rubin
authors.forename: P E
authors.initials: PE
authors.lastname: Saigo
authors.forename: D
authors.initials: D
authors.lastname: Chapman
authors.forename: J L
authors.initials: JL
authors.lastname: Lewis
authors.forename: W B
authors.initials: WB
authors.lastname: Jones
authors.forename: T B
authors.initials: TB
authors.lastname: Hakes
authors.forename: M
authors.initials: M
authors.lastname: Markman
authors.forename: B
authors.initials: B
authors.lastname: Reichman
authors.forename: W J
authors.initials: WJ
authors.lastname: Hoskins
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage*; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D015996:Survival Rate
chemical_list: D002945:Cisplatin